Urologic Oncology News: Prostate, Bladder and Kidney Cancer
- Specific molecular alterations explain discordance between genomic and clinical risk in localized prostate cancer Retrospective · Clin Cancer Res · 2026-11-18
Across 287,145 patients, TP53, PTEN, AR activity and RB1 status were linked to discordance between Decipher Genomic Classifier and NCCN risk groups; adverse molecular features added prognostic information for distant metastasis in high-risk patients.
Why it matters: Suggests molecular feature profiling could refine risk stratification beyond genomic classifier scores alone in high-risk disease.
- Opioid-free anesthesia shows no significant benefit over opioid-based technique in prostatectomy RCT · World J Urol · 2026-11-18
In a 57-patient randomized trial, opioid-free anesthesia did not significantly reduce 24-hour postoperative oxycodone consumption or pain scores compared with remifentanil-based anesthesia during laparoscopic radical prostatectomy.
Why it matters: Suggests opioid-free protocols are not clearly superior for postoperative analgesia in this setting, though trial was underpowered for equivalence.
- Elevated neutrophil-lymphocyte ratio linked to worse survival on 177Lu-PSMA-617 therapy Retrospective · Prostate Cancer Prostatic Dis · 2026-11-16
In a two-institution retrospective analysis of 501 mCRPC patients treated with 177Lu-PSMA-617 after taxane therapy, a neutrophil-lymphocyte ratio above 3 at the first cycle was independently associated with worse survival, with persistently elevated NLR through cycle 2 linked to the poorest outcomes.
Why it matters: Raises the question of whether a simple blood ratio could help flag patients needing closer monitoring during PSMA radioligand therapy, but needs prospective validation.
- Systematic review underlying new ACS guideline summarizes benefits and harms of PSA screening Meta-analysis · Cancer · 2026-11-13
A systematic review of 29 publications, including 23 from six randomized trials (PLCO, CAP, ERSPC, Goteborg-1, Rotterdam Pilot 1, ProScreen) and four observational studies, found PSA screening was associated with reduced incidence of advanced/metastatic disease and, in some trials, reduced prostate cancer-specific mortality, though findings on mortality were inconsistent.
Why it matters: Provides the evidence base, drawn from a systematic review of RCTs and observational studies, behind the updated ACS PSA screening guideline, useful for shared decision-making conversations.
- Meta-analysis: active surveillance shows similar mortality to surgery, but watchful waiting worse Meta-analysis · Clin Genitourin Cancer · 2026-11-13
Across 12 studies (36,993 patients), active surveillance showed no significant difference in cancer-specific or all-cause mortality versus radical prostatectomy, though evidence was underpowered; watchful waiting was associated with significantly higher cancer-specific and all-cause mortality than surgery.
Why it matters: Suggests active surveillance and watchful waiting are not interchangeable, though the active surveillance comparison remains underpowered.
- PSMA total tumor volume outpredicts SUV and PSA for overall survival in large PET registry Retrospective · J Nucl Med · 2026-11-13
Among 13,893 prostate cancer patients in the PROMISE PET Registry split into development (n=9271) and validation (n=4622) cohorts, PSMA total tumor volume predicted overall survival in the validation cohort with a C-index of 0.78 (95% CI, 0.77-0.80), outperforming whole-body SUVmean (0.62; 95% CI, 0.61-0.64) and PSA at PET (0.71; 95% CI, 0.69-0.72), and performing similarly to PSMA total lesion uptake (0.78) and PSA times TTV (0.77).
Why it matters: A straightforward volumetric PSMA PET measurement may offer a more reliable way to stratify overall survival risk than SUV or PSA alone.
- FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA PET agent FDA action · OncLive · 2026-11-12
FDA granted Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA, a PSMA PET imaging agent, for detecting biochemically recurrent prostate cancer.
Why it matters: Designation may accelerate review of a new long-lived PSMA PET tracer option for recurrence imaging.
- NCCN adds ArteraAI post-prostatectomy test to guideline for biochemical recurrence risk News · Targeted Oncology · 2026-11-12
NCCN guidelines now include the ArteraAI test, an AI-based prognostic tool, for risk assessment after radical prostatectomy in the setting of biochemical recurrence.
Why it matters: Signals growing guideline incorporation of AI-based prognostic biomarkers into routine post-prostatectomy decision-making.
- ctDNA positivity before SBRT predicts rapid progression in oligoprogressive CRPC Retrospective · JAMA Netw Open · 2026-11-12
In this prespecified secondary analysis of the phase 2 TRAP trial, 19 of 77 evaluable patients (24.7%) were ctDNA-positive before SBRT; their 6-month progression-free survival was 21.1% versus 58.3% for ctDNA-negative patients, with median PFS of 3.0 versus 7.8 months (P = .003). Median overall survival was 27.2 months for ctDNA-positive patients and 33.6 months for ctDNA-negative patients.
Why it matters: Baseline ctDNA status may help identify oligoprogressive CRPC patients less likely to benefit from SBRT, supporting its potential use in selecting candidates for metastasis-directed therapy versus earlier systemic change.
- CT adds little over pelvic MRI for nodal staging in higher-risk prostate cancer, both poor vs pathology Retrospective · World J Urol · 2026-11-12
In 323 patients with unfavorable intermediate- or high-risk prostate cancer, MRI and CT showed only moderate agreement for nodal staging and both had low sensitivity (≤20%) versus surgical pathology; PSMA PET/CT performed better (AUC 0.86) in a subgroup with molecular imaging.
Why it matters: Raises the question of whether conventional CT adds meaningful nodal staging value when PSMA PET is available.
- Cretostimogene reduces NMIBC recurrence risk by 68% in Phase 3 PIVOT-006, company reports Phase 3 RCT · Dealroom · 2026-11-16
CG Oncology announced topline results from its Phase 3 PIVOT-006 trial, reporting that cretostimogene reduced recurrence risk by 68% in NMIBC patients, with no patients discontinuing treatment due to related side effects. Full data and statistical details have not yet been disclosed.
Why it matters: A company-reported Phase 3 topline result suggests cretostimogene may offer a new intravesical option for NMIBC, pending full data disclosure and FDA review.
- Pooled phase 2/3 trials show 78% complete response with UGN-102 in recurrent low-grade NMIBC Retrospective · Urol Oncol · 2026-11-17
A pooled exploratory analysis of four phase 2/3 trials found 78.3% complete response at 3 months with UGN-102 in recurrent low-grade intermediate-risk NMIBC, with 79.7% remaining event-free at 12 months after response in the ATLAS/ENVISION subset. Within the ATLAS trial, UGN-102 showed higher 3-month CR (73.7% vs 51.5%) and higher 12-month event-free probability after CR (68.8% vs 44.2%) than TURBT.
Why it matters: Pooled phase 2/3 data add longer-term efficacy and safety evidence for UGN-102, an FDA-approved nonsurgical option for recurrent low-grade NMIBC.
- Adding trilaciclib to chemo-immunotherapy did not improve PFS in advanced urothelial cancer RCT · Clin Genitourin Cancer · 2026-11-17
In a randomized phase 2 trial of 92 patients with advanced urothelial carcinoma, adding trilaciclib to platinum chemotherapy plus avelumab maintenance showed modest myeloprotective effects but no improvement in progression-free survival (6.6 vs 6.1 months overall, HR 0.94).
Why it matters: Indicates trilaciclib added to standard first-line chemoimmunotherapy does not improve antitumor efficacy in advanced urothelial cancer.
- Continuous antibiotic prophylaxis after cystectomy tied to more resistant organisms, no infection benefit Retrospective · BJU Int · 2026-11-17
In a single-center retrospective cohort of 223 cystectomy patients, continuous oral antibiotic prophylaxis until stent removal showed no reduction in surgical site infection, UTI, or readmission compared to a short stent-removal course, but was linked to more Pseudomonas and other uncovered organism isolation.
Why it matters: Raises the question of whether prolonged antibiotic prophylaxis after cystectomy offers any benefit while potentially increasing resistant organism isolation.
- Biomarker-guided surveillance cuts cystoscopies in NMIBC without clear oncologic harm Meta-analysis · World J Urol · 2026-11-16
A meta-analysis of two randomized trials (DaBlaCa-15 and UroFollow, 606 patients, 590 in primary analyses) found biomarker-guided surveillance reduced cystoscopy use by 55.8% and 74.9% in the two trials respectively, with no significant difference in any recurrence (RR 1.04, 95% CI 0.77-1.41), high-grade recurrence or progression (RR 1.03, 95% CI 0.61-1.74), or progression to muscle-invasive/metastatic disease (RR 0.57, 95% CI 0.12-2.67); non-inferiority was not established.
Why it matters: Offers early randomized support for reducing cystoscopy burden in NMIBC surveillance, but confirmatory data are needed before changing guideline-based follow-up.
- FDA approves durvalumab with enfortumab vedotin for muscle-invasive bladder cancer FDA approval · FDA · 2026-11-13
FDA approved the perioperative combination of durvalumab (an immune checkpoint inhibitor) and enfortumab vedotin-ejfv for muscle-invasive bladder cancer.
Why it matters: Adds a new FDA-approved perioperative regimen option for muscle-invasive bladder cancer.
- Claims data: psychiatric diagnoses common after cystectomy regardless of diversion type Retrospective · Urology · 2026-11-15
In a TriNetX claims analysis of over 13,000 cystectomy patients, neobladder recipients had a transient excess of new mood disorder diagnoses in the first month (RR 1.81) that equalized with ileal conduit patients by 6 months; roughly a quarter of all patients had a new or recurrent psychiatric diagnosis by 5 years.
Why it matters: Hypothesis generating from claims data lacking clinical detail; suggests mental health needs after cystectomy are common and not clearly tied to diversion type long-term.
- Propensity-matched study inconclusive on histologic subtype risk in bladder-preserved NMIBC Retrospective · Clin Genitourin Cancer · 2026-11-15
In a propensity score-matched cohort of 456 NMIBC patients, those with histologic subtypes, divergent differentiation or neuroendocrine components had imprecise progression (HR 1.30, 95% CI 0.36-4.66) and recurrence (HR 0.59, 95% CI 0.27-1.31) estimates versus conventional urothelial carcinoma.
Why it matters: Raises the question of bladder-preserving approaches in variant histology NMIBC but the small event count and wide confidence intervals prevent any practice conclusion.
- Lynch syndrome carriers show 4.4% urothelial cancer rate, mostly upper tract Retrospective · JCO Precis Oncol · 2026-11-14
In a registry of 3,274 genetically confirmed Lynch syndrome carriers, 144 (4.4%) developed 224 urothelial carcinomas, over half in the upper urinary tract; MSH2/EPCAM variant carriers had higher risk (HR 4.43) than those with other MMR gene variants.
Why it matters: Raises the question of whether MSH2/EPCAM carriers warrant closer urothelial surveillance than other Lynch syndrome genotypes, pending prospective validation.
- Delphi consensus of 73 UTUC experts agrees on 32 of 40 statements for non-metastatic UTUC care Guideline · Nat Rev Urol · 2026-11-13
A two-round, web-based Delphi survey of 73 international UTUC experts (urologists and medical oncologists) rated 40 statements on diagnosis, staging, and treatment of non-metastatic upper tract urothelial carcinoma. Consensus was reached on 32 of 40 statements (80%) across both rounds, offering expert-informed guidance given limited high-level evidence in this disease.
Why it matters: Offers pragmatic expert consensus to help reduce practice variability in non-metastatic UTUC, an area with limited randomized trial evidence, though it is not a formal clinical guideline.
- Single-port robotic nephroureterectomy via lower anterior access feasible in multicenter series Retrospective · Eur Urol · 2026-11-07
In 47 patients across five centers, single-port retroperitoneal nephroureterectomy with bladder cuff excision via a single extraperitoneal incision achieved 76.7% pentafecta at 12 months, with 6% grade 3+ complications and 15% recurrence at median 12.3-month follow-up.
Why it matters: Describes an emerging single-port surgical technique for UTUC; comparative data against standard approaches are still needed.
- Commentary: pathogenic germline variants in urinary tract cancers are common but often missed Review · Renal & Urology News · 2026-11-04
A commentary piece discusses evidence that pathogenic germline variants are prevalent among patients with urinary tract cancers yet frequently go undetected on standard testing pathways.
Why it matters: Underscores the gap in germline testing uptake in urothelial cancers, consistent with prior reports of low testing rates in UTUC.
- Germline testing performed in under 5% of UTUC patients in claims analysis Retrospective · JCO Oncol Pract · 2026-10-31
A nationwide claims-based analysis of 4,783 patients with newly diagnosed UTUC found only 4.5% underwent germline testing, with no increase from 2015-2023, including just 5.6% of those diagnosed before age 50 who meet guideline criteria.
Why it matters: Raises the question of whether UTUC care pathways are failing to integrate germline evaluation despite guideline endorsement for Lynch syndrome screening; claims data cannot capture reasons testing was not ordered.
- Meta-analysis links neoadjuvant chemotherapy to better survival before nephroureterectomy in UTUC Meta-analysis · Eur Urol Oncol · 2026-10-27
Pooling 30 studies (2384 patients, mostly retrospective) on neoadjuvant chemotherapy for upper tract urothelial carcinoma, pathologic complete response occurred in 11% and downstaging in 20%; neoadjuvant chemotherapy was associated with HR 0.56 for overall survival and 0.47 for cancer-specific survival versus upfront surgery.
Why it matters: Adds support for a neoadjuvant chemotherapy approach in UTUC, though most included data are retrospective and immunotherapy evidence remains limited.
- UroVysion shows modest sensitivity but high PPV for UTUC in cytology-negative patients Retrospective · World J Urol · 2026-10-20
In a retrospective study of 1,256 patients with upper tract lesions and negative urinary cytology, UroVysion FISH had 66.9% sensitivity, 82.7% specificity, and 94.0% PPV for UTUC, and was associated with high-grade disease, lymphovascular invasion, and muscle invasion.
Why it matters: Raises the question of UroVysion as an adjunct when cytology is negative, though its low NPV limits its use for ruling out UTUC.
Urology clinical trials · Urology podcasts · Urology videos · Meetings · Daily edition archive
Loading today's edition…